© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 16, 1215-1223,
August 15, 2001
© 2001 Oxford University Press
Family History of Breast and Ovarian Cancers and BRCA1 and BRCA2 Mutations in a Population-Based Series of Early-Onset Breast Cancer
Affiliations of authors: N. Loman, O. Johannsson, Å. Borg (Department of Oncology), U. Kristoffersson (Department of Clinical Genetics), Lund University Hospital, Sweden.
Correspondence to: Niklas Loman, M.D., Department of Oncology, Lund University Hospital, SE-221 85 Lund, Sweden (e-mail: Niklas.Loman{at}onk.lu.se).
Background: BRCA1 and BRCA2 are the two major susceptibility genes involved in hereditary breast cancer. This study was undertaken to provide reliable population-based estimates of genetic influence and to characterize the nature and prevalence of BRCA1 and BRCA2 germline mutations in early-onset breast cancer. Methods: In a series comprising all women diagnosed with breast cancer under the age of 41 years in southern Sweden during 1990 through 1995 (n = 262), family history of cancer was evaluated in 95% (n = 250) of the case subjects and germline mutations in BRCA1 and BRCA2 were analyzed in 89% (n = 234). All statistical tests were two-sided. Results: A total of 97 case subjects had at least one first- or second-degree relative with breast or ovarian cancer; 34 (14%; 95% confidence interval [CI] = 9.6% to 18%) cases had at least two first- or second-degree relatives, 22 (8.8%; 95%CI = 5.3% to 12%) had one first-degree relative, and 41 (16%; 95% CI = 12% to 21%) had one second-degree relative with either cancer. If two females affected with breast or ovarian cancer who were related through an unaffected male were also defined as first-degree relatives, then a higher number of case subjects, 120 (48%; 95% CI = 42% to 54%), had at least one first-degree or second-degree relative with breast or ovarian cancer. Sixteen (6.8%; 95% CI = 4.0% to 11%) BRCA1 mutation carriers and five (2.1%; 95% CI = 0.70% to 4.9%) BRCA2 mutation carriers were identified. Among case subjects with one first- or more than one first- or second-degree relative with breast or ovarian cancer, BRCA mutations were more frequent (P<.001) than among the case subjects without this degree of family history. BRCA mutations were also statistically significantly more common among women with bilateral breast cancer than among women with unilateral breast cancer (P = .002). BRCA mutations were more common among younger case subjects than among older ones (P = .0027). Conclusions: Almost half (48%) of women in southern Sweden with early-onset breast cancer have some family history of breast or ovarian cancer, and 9.0% of early-onset breast cancer cases are associated with a germline mutation in BRCA1 or BRCA2. Mutation carriers were more prevalent among young women, women with at least one first- or second-degree relative with breast or ovarian cancer, and women with bilateral breast cancer.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Ersahin, M. Chivukula, R. Bhargava, and D. J. Dabbs Basal-Like Subtype Breast Cancers in Women Older Than 40 Years of Age International Journal of Surgical Pathology, February 1, 2010; 18(1): 42 - 47. [Abstract] [PDF]
|
|
|
|
 |
|
 D G R Evans, F Lalloo, A Cramer, E A Jones, F Knox, E Amir, and A Howell Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing J. Med. Genet., December 1, 2009; 46(12): 811 - 817. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. C Ericson, M. I. Ivarsson, E. Sonestedt, B. Gullberg, J. Carlson, H. Olsson, and E. Wirfalt Increased breast cancer risk at high plasma folate concentrations among women with the MTHFR 677T allele Am. J. Clinical Nutrition, November 1, 2009; 90(5): 1380 - 1389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hickey, M. Peate, C.M. Saunders, and M. Friedlander Breast cancer in young women and its impact on reproductive function Hum. Reprod. Update, May 1, 2009; 15(3): 323 - 339. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Ericson, E. Sonestedt, M. I.L. Ivarsson, B. Gullberg, J. Carlson, H. Olsson, and E. Wirfalt Folate Intake, Methylenetetrahydrofolate Reductase Polymorphisms, and Breast Cancer Risk in Women from the Malmo Diet and Cancer Cohort Cancer Epidemiol. Biomarkers Prev., April 1, 2009; 18(4): 1101 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Y-K Chan, W Liu, J-R Long, S-P Yip, S-Y Chan, X-O Shu, D T-T Chua, A N-Y Cheung, J C-Y Ching, H Cai, et al. Functional polymorphisms in the BRCA1 promoter influence transcription and are associated with decreased risk for breast cancer in Chinese women J. Med. Genet., January 1, 2009; 46(1): 32 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. John, A. Miron, G. Gong, A. I. Phipps, A. Felberg, F. P. Li, D. W. West, and A. S. Whittemore Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups JAMA, December 26, 2007; 298(24): 2869 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Ericson, E. Sonestedt, B. Gullberg, H. Olsson, and E. Wirfalt High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmo Diet and Cancer cohort Am. J. Clinical Nutrition, August 1, 2007; 86(2): 434 - 443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Henningson, U. Johansson, A. Borg, H. Olsson, and H. Jernstrom CYP17 genotype is associated with short menstrual cycles, early oral contraceptive use and BRCA mutation status in young healthy women Mol. Hum. Reprod., April 1, 2007; 13(4): 231 - 236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. E. Malone, J. R. Daling, D. R. Doody, L. Hsu, L. Bernstein, R. J. Coates, P. A. Marchbanks, M. S. Simon, J. A. McDonald, S. A. Norman, et al. Prevalence and Predictors of BRCA1 and BRCA2 Mutations in a Population-Based Study of Breast Cancer in White and Black American Women Ages 35 to 64 Years Cancer Res., August 15, 2006; 66(16): 8297 - 8308. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P van der Groep, A Bouter, R van der Zanden, I Siccama, F H Menko, J J P Gille, C van Kalken, E van der Wall, R H M Verheijen, and P J van Diest Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data J. Clin. Pathol., June 1, 2006; 59(6): 611 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Jonsson, T. L. Naylor, J. Vallon-Christersson, J. Staaf, J. Huang, M. R. Ward, J. D. Greshock, L. Luts, H. Olsson, N. Rahman, et al. Distinct Genomic Profiles in Hereditary Breast Tumors Identified by Array-Based Comparative Genomic Hybridization Cancer Res., September 1, 2005; 65(17): 7612 - 7621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. B. Claus, S. Petruzella, E. Matloff, and D. Carter Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ JAMA, February 23, 2005; 293(8): 964 - 969. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Sun, X. Miao, J. Wang, W. Tan, Y. Zhou, C. Yu, and D. Lin Functional Phe31Ile polymorphism in Aurora A and risk of breast carcinoma Carcinogenesis, November 1, 2004; 25(11): 2225 - 2230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Angelopoulos, V Barbounis, S Livadas, D Kaltsas, and G Tolis Effects of estrogen deprivation due to breast cancer treatment Endocr. Relat. Cancer, September 1, 2004; 11(3): 523 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, and F Lalloo A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO J. Med. Genet., June 1, 2004; 41(6): 474 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Choi, M. H. Lee, A. E. Bale, D. Carter, and B. G. Haffty Incidence of BRCA1 and BRCA2 Mutations in Young Korean Breast Cancer Patients J. Clin. Oncol., May 1, 2004; 22(9): 1638 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhou, C. Yu, X. Miao, W. Tan, G. Liang, P. Xiong, T. Sun, and D. Lin Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes Carcinogenesis, March 1, 2004; 25(3): 399 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H Ozcelik, J A Knight, G Glendon, H Yazici, N Carson, P J Ainsworth, S A M Taylor, H Feilotter, R F Carter, N F Boyd, et al. Individual and family characteristics associated with protein truncating BRCA1 and BRCA2 mutations in an Ontario population based series from the Cooperative Family Registry for Breast Cancer Studies J. Med. Genet., August 1, 2003; 40(8): e91 - 91. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kattlove and R. J. Winn Ongoing Care of Patients After Primary Treatment for Their Cancer CA Cancer J Clin, May 1, 2003; 53(3): 172 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Fleming, J. D. Potter, C. J. Ramirez, G. K. Ostrander, and E. A. Ostrander Understanding missense mutations in the BRCA1 gene: An evolutionary approach PNAS, February 4, 2003; 100(3): 1151 - 1156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sobol, N. Vey, R. Sauvan, N. Philip, T. Noguchi, and F. Eisinger Re: Familial Multiple Myeloma: a Family Study and Review of the Literature J Natl Cancer Inst, March 20, 2002; 94(6): 461 - 462. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Berry Role of Population-Based Studies in Assessing Genetic Cancer Risk J Natl Cancer Inst, August 15, 2001; 93(16): 1188 - 1189. [Full Text] [PDF]
|
|